Comparative Pharmacology
Head-to-head clinical analysis: DROXIDOPA versus VASOXYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROXIDOPA versus VASOXYL.
DROXIDOPA vs VASOXYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction and increased blood pressure.
100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.
Intravenous bolus: 0.1-0.2 mg per dose; intravenous infusion: 0.1-0.2 mg/min; intramuscular or subcutaneous: 0.5-1 mg per dose.
None Documented
None Documented
2–3 hours; terminal half-life approximately 2.5 hours, requiring 3–4 times daily dosing to maintain plasma levels.
Clinical Note
moderateDroxidopa + Torasemide
"Droxidopa may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateDroxidopa + Etacrynic acid
"Droxidopa may increase the hypokalemic activities of Etacrynic acid."
Clinical Note
moderateDroxidopa + Furosemide
"Droxidopa may increase the hypokalemic activities of Furosemide."
Clinical Note
moderateDroxidopa + Bumetanide
"Droxidopa may increase the hypokalemic activities of Bumetanide."
Terminal elimination half-life is 2.5-3.0 hours; clinically relevant for dosing intervals in hypotension management.
Renal: ~75% as unchanged drug and metabolites (including 3-O-methyldroxidopa and other conjugates); biliary/fecal: minimal (<5%).
Primarily renal excretion as unchanged drug and metabolites (phenylephrine is deaminated by MAO). Approximately 80-85% excreted in urine within 24 hours; negligible biliary/fecal elimination.
Category C
Category C
Vasopressor
Vasopressor